Naltrexone Treatment Centers in Delaware

naltrexone is approved for opioid use disorder involving any opioid — heroin, fentanyl, prescription oxycodone, hydrocodone, or morphine. Delaware clinicians treat patients whose OUD started with a pain prescription just as readily as those using illicit opioids.

Vivitrol monthly cost without insurance typically falls between $1,100 and $1,500 per injection in Delaware. The manufacturer Alkermes offers a patient-assistance co-pay savings card; state-funded programs also cover Vivitrol for uninsured patients in many counties.

Delaware Medicaid (Diamond State Health Plan) managed-care organizations (MCOs) in Delaware all cover MAT, but formulary details, prior-authorization rules, and in-network provider lists vary. Choose the MCO whose network includes your preferred naltrexone providers; you can usually switch plans once a year.

Yes. Parity law requires equal coverage for the medication and counseling components of MAT. Counseling copays often match mental-health visit copays (typically $20–$50 for commercial plans in Delaware). Providers bill counseling and medication separately.

No. A 2022 Department of Justice enforcement action confirmed that Delaware drug courts cannot ban FDA-approved MAT medications; doing so violates the ADA. Patients in drug court have the legal right to remain on their prescribed naltrexone regimen.

Common reasons include lifestyle stabilization (patient and clinician agree to taper), cost barriers, side effects, travel or employment disruption, and desire to try naltrexone after tapering. Many patients resume treatment later — clinics welcome return visits without judgment.

Avoid benzodiazepines, alcohol, and long-acting opioids for 6–12 hours before induction to reduce sedation risk. For buprenorphine, let the clinician know your last opioid use time so they can time the first dose to avoid precipitated withdrawal.

Delaware programs generally recommend arranging a ride for the first induction visit, since initial drowsiness is common. After the first 1–2 weeks at a stable dose, patients typically resume driving and most daily activities without restriction.

Yes. Decades of research support the long-term safety of methadone, buprenorphine, and naltrexone when appropriately prescribed. Long-term MAT is associated with lower mortality, reduced infectious disease, and improved quality of life. Delaware patients frequently remain on MAT for years without medical complications.

No — abrupt discontinuation is dangerous for the pregnancy. Call your Delaware MAT clinic right away; the team will coordinate with obstetrics to continue medication safely and arrange any dose adjustments needed as the pregnancy progresses.

Yes. Delaware Medicaid (Diamond State Health Plan) covers individual therapy, group sessions, and care coordination at Delaware MAT clinics without separate deductibles in most plans. Peer-recovery support services are also covered in Delaware.

Under the ADA, you cannot be fired solely because you are enrolled in naltrexone. Current illegal drug use is not protected, but lawful MAT enrollment is. Safety-sensitive roles (CDL, aviation) have additional rules — an employment attorney can review your specific situation.